Preventive Cardiovascular

Impact of PCSK9 Inhibitors

Impact of PCSK9 Inhibitors in Patients

2022, N = 483

Preventive Cardiology patients on PCSK9 inhibitors experienced significant reductions in low-density lipoprotein (LDL) cholesterol levels.

HDL = high-density lipoprotein, LDL = low-density lipoprotein

Source: EPIC